ATXA Therapeutics

Phase 1

Dublin, IrelandFounded 2015atxatherapeutics.com

ATXA Therapeutics, founded in 2015, is pioneering a new therapeutic approach for cardiopulmonary diseases by targeting the thromboxane prostanoid receptor (TP). Its lead asset, NTP42, has demonstrated promising preclinical efficacy across multiple disease hallmarks of PAH and is positioned as a potential platform therapy for related conditions like heart failure and pulmonary fibrosis. The company is backed by prestigious EU and Irish grants, has built a strong IP estate, and is led by a team with deep expertise in prostanoid receptor biology and drug development.

Founded

2015

Focus

Small Molecules

AI Company Overview

Technology Platform

Platform for developing novel, highly selective small molecule antagonists of the Thromboxane Prostanoid (TP) receptor, a key driver of vasoconstriction, proliferation, inflammation, and fibrosis in cardiopulmonary diseases.

Funding History

Total raised: $29.3M

Series A$12MSeroba Life SciencesNov 15, 2022

Grant$2.5MEnterprise IrelandSep 15, 2021

Series A$12MSeroba Life SciencesJun 15, 2020

Seed$2.8MEnterprise IrelandJun 15, 2016

Opportunities

NTP42 has platform potential to treat multiple cardiopulmonary diseases with high unmet need and blockbuster market potential, including heart failure and pulmonary fibrosis.

Orphan drug designations for PAH provide a faster regulatory pathway and market exclusivity.

The novel mechanism of action allows for differentiation and potential combination use with existing standard-of-care therapies.

Risk Factors

The company is at an early clinical stage with a novel mechanism, facing significant clinical development and regulatory risks.

Advancing through late-stage trials requires substantial capital, creating financing risk.

As a small biotech, eventual commercialization may depend on securing a partnership with a larger pharmaceutical company.

Competitive Landscape

In PAH, ATXA faces competition from established vasodilator therapies (ERAs, PDE5 inhibitors, prostacyclins). However, NTP42's first-in-class TP antagonist mechanism aims to be disease-modifying rather than just symptomatic, offering a key point of differentiation. The oral formulation also provides an advantage over invasive existing therapies. The competitive field for TP antagonists in cardiopulmonary disease is not saturated.